The following presentations are included among the 14 presentations at ASH to feature clinical and non-clinical data on ponatinib.
My questions are, who fund these? Is this pure science, or, if Ariad monetizes this early research, are there royalities involved?
Presenter:
Deborah White, Ph.D. (University of Adelaide, Australia)
Location:
Hall GH
Title:
Ponatinib Is Active Against the CUX1-FGFR1 Fusion Kinase and Against Imatinib Resistance Mutations of the FIP1L1-PDGFRa Fusion Kinase and of KIT
Poster Session:
Myeloproliferative Syndromes: Poster III
Date & Time:
Monday, December 12, 2011, 6:00 - 8:00 p.m. (PST)
Abstract No.:
3848
Presenter:
Els Lierman, Ph.D. (Center for Human Genetics, Katholieke Universiteit Leuven, Belgium)
Location:
Hall GH
Title:
Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutations
Oral Session:
Molecular Pharmacology, Drug Resistance: Targeting Chemoresistant Cells and Niche
Date & Time:
Tuesday, December 13, 2011, 8:45 a.m. (PST)
Abstract No.:
930
Presenter:
Catherine C. Smith, M.D. (The University of California San Francisco)
Location:
Room 25
